Staff Profile
James Murray
Senior Research Technician
- Email: james.murray2@ncl.ac.uk
- Address: Leukaemia Research Cytogenetics Group
Wolfson Childhood Cancer Research Centre
Northern Institute for Cancer Research
Newcastle University
Level 6, Herschel Building
Brewery Lane
Newcastle upon Tyne
NE1 7RU
Publications
- Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, Wragg C, Moppett J, Cummins M, Tunstall O, Parker CA, Saha V, Goulden N, Vora A, Moorman AV, Harrison CJ. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 2016, 127(18), 2214-2218.
- McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ. Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib. Clinical Cancer Research 2017, 23(8), 2050-2060.
- Mukhopadhyay A, Dixon M, Mulligan E, Schuhwerk H, Murray J, Quinn J, Van Nest L, Van Criekinge W, Curtin N, Edmondson R. Evaluation of different methods to assess homologous recombination status and sensitivity to parp inhibitors in ovarian cancer. In: The 15th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2014). 2014, Melbourne, Australia: Lippincott Williams & Wilkins.
- Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer 2014, 110, 1977-1984.
- Patterson MJ, Murray J, Curtin NJ. Stability of PARP Inhibition by BMN 673 in Human PBMCs (and Leukaemic Cell Cultures). In: 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2012, Dublin, Ireland: Pergamon.